Agomab Therapeutics NV (AGMB)

Biological Products, (No Diagnostic Substances) · market cap $372M · as of 2026-07-22

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Agomab Therapeutics NV (AGMB) is a clinical-stage Belgian biotech with 57 employees and a ~$583M market cap, focused on a single disclosed asset: AGMB-129, currently in Phase 2 for fibrostenotic Crohn's disease. The company's mechanism of action for AGMB-129 is not disclosed in available data. An earnings release is scheduled for 2026-07-23.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
AGMB-129	Phase 2	Fibrostenotic Crohn's Disease

Price & technical context

3-month

-6.5%

6-month

+5.8%

12-month

—

52-wk range

$9.61–$17.82

vs 50-day MA

-15.0%

vs 200-day MA

—

Realized vol

91.3%

Max drawdown

-42.7%

Daily closes through 2026-09-30. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for AGMB (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.